Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Pre-close trading update

22 Jul 2010 07:00

RNS Number : 7231P
Cello Group plc
22 July 2010
 



22 July 2010

 

Cello Group plc

 

Pre-close trading update

 

Cello Group (AIM: CLL, 'Cello', or 'the Group'), the leading independent market research and consulting group, publishes a trading update for the six months to 30 June 2010. Cello has continued to trade well and will show like for like income growth and double digit operating profit growth for the first half of the financial year.

 

The Group continues to experience growing income from its international blue chip client base, with particular growth arising from the US, where further organic investment is planned for the second half of the year. Income from UK clients has held up well, with several notable private sector wins, while as anticipated there are likely to be further declines in public sector income over the coming months.

 

The like for like income growth achieved, combined with a lower cost base as a result of pro-active action taken in 2009, are expected to lead to a healthy improvement in profitability in 2010.

 

Divisional trading

 

The Research and Consulting division continues to trade strongly, returning to like for like income growth. This has been driven by continued robustness in core client activity levels, most notably in pharmaceutical and health related sectors, as well as the growing international revenues.

 

The recent investments made to increase the Group's overseas capabilities have begun to bear fruit. Cello recently relocated its US business into a new office in New York. This will act as a resource hub for other Group brands as they continue to build their US client base.

 

New business activity has increased markedly, with notable major project wins from ITV, GSK, Visa Europe, 3M, AG Barr, BA, Expedia, Heineken, Mars Petfood, Unilever, Electronic Arts, Sony, Nokia, Adidas, Miele, Eurostar, MerckSerono, HP, Canon, Epson, Brother, P&G Airwave and Green-works. As a result, the division has a strong pipeline of committed work into the second half of the year, which will more than offset the expected decline in public sector work.

 

Tangible, Cello's response communications business, as expected, saw slight like for like decline in operating income in the first half. The income decline largely occurred due to certain public sector clients not repeating their programmes in 2010.

 

The business now operates out of three office hubs in Edinburgh, London and Cheltenham which is yielding both clear cost benefits, as well as professional and client benefits. A major cost reduction exercise was also undertaken last year, which with these structural changes, mean that operating margins in the current financial year have been substantially protected.

 

There has been a good series of major client wins by Tangible including Scottish and Southern Energy, Sainsbury's Bank, Reckitt Benckiser, O2, Chartis, SPX, SQA. Macmillan Cancer Care, The Sun (Scottish), Avon, Pfizer, Ben & Jerrys, Nandos and Matalan. The benefit of many of these wins will be seen in the second half of the year.

 

Given Tangible's strong flow of private sector client wins, and a more efficient cost base, the Group is confident that Tangible will be substantially ahead of 2009 on a full year basis.

Full year outlook

 

Revenue visibility for the next quarter remains solid and, subject to proper conversion of existing client opportunities, the Board is optimistic for a good full year outcome.

 

Mark Scott, Cello Chief Executive, commented:

 

 "We are pleased with our trading performance and like for like income growth levels in the first half of the year. We are seeing the benefits from our international investment programme initiated two years ago.

 

"The continued growth of income from our long term multi-national blue chip client base, both in the UK and internationally, has more than offset the expected weaker performance from our UK public sector clients. We are set well for the remainder of the year.

 

"Separately I am also delighted to welcome Paul Walton to the Board. As a senior client advisor and strategist, he will undoubtedly continue to make a substantial contribution across the Group"

 

The Group expects to publish its interim results on Tuesday 14 September 2010.

 

Enquiries:

 

Cello Group

020 7812 8460

Mark Scott, Chief Executive

Mark Bentley, Finance Director

Altium

020 7484 4040

Ben Thorne

Paul Chamberlain

College Hill

020 7457 2020

Adrian Duffield/Rozi Morris

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAKXFAFFEEFF
Date   Source Headline
2nd Oct 20198:40 amRNSDisposal
18th Sep 20197:00 amRNSInterim Results
23rd Aug 201910:40 amRNSHolding(s) in Company
16th Aug 20197:00 amRNSAcquisition of ISS
6th Aug 20193:07 pmRNSTotal Voting Rights
6th Aug 20197:00 amRNSNotification of Half Year Results
18th Jul 20197:00 amRNSPre-close Trading Update
20th Jun 20194:29 pmRNSDirector/PDMR Shareholding
10th Jun 20199:41 amRNSTotal Voting Rights
24th May 201912:45 pmRNSBlock listing Interim Review
20th May 20194:29 pmRNSIssue of Equity
15th May 20197:00 amRNSHolding(s) in Company
8th May 20191:30 pmRNSResult of AGM
8th May 20197:00 amRNSAGM Statement
1st May 201912:15 pmRNSTotal Voting Rights
15th Apr 201911:12 amRNSAnnual Report and Notice of AGM
10th Apr 20197:00 amRNSCapital Markets Event
4th Apr 201910:00 amRNSTotal Voting Rights
27th Mar 20191:00 pmRNSHolding(s) in Company
21st Mar 20193:10 pmRNSDirector/PDMR Shareholding
21st Mar 20197:00 amRNSPreliminary Results
6th Mar 20191:51 pmRNSHolding(s) in Company
7th Feb 20197:00 amRNSNotice of Full Year Results
17th Jan 20197:00 amRNSPre-Close Trading Statement
14th Dec 20189:24 amRNSBlock Listing Update
23rd Nov 20183:45 pmRNSHolding(s) in Company
19th Nov 20182:45 pmRNSHolding(s) in Company
12th Nov 201811:30 amRNSDirectorate Change
5th Nov 20182:00 pmRNSDirectorate Change
31st Oct 20183:30 pmRNSDirector/PDMR Shareholding
10th Oct 20187:00 amRNSDirector/PDMR Shareholding
2nd Oct 20187:00 amRNSAppointment of Executive Director
25th Sep 20181:00 pmRNSDirector/PDMR Shareholding
25th Sep 20187:00 amRNSDirector/PDMR Shareholding
24th Sep 201811:39 amRNSTransfer of FTSE classification to Healthcare
21st Sep 201810:15 amRNSDirector/PDMR Shareholding
20th Sep 20184:00 pmRNSHolding(s) in Company
20th Sep 20187:00 amRNSDirector/PDMR Shareholding
19th Sep 20187:00 amRNSInterim Results
22nd Aug 20181:51 pmRNSHolding(s) in Company
17th Aug 20187:00 amRNSNotification of Half Year Results
16th Aug 20182:00 pmRNSTotal Voting Rights
16th Aug 20181:30 pmRNSBoard Changes
23rd Jul 20187:00 amRNSHolding(s) in Company
19th Jul 20187:00 amRNSPre-close Trading Update
17th Jul 20187:00 amRNSChange of registered office
4th Jul 20181:53 pmRNSHolding(s) in Company
27th Jun 201812:46 pmRNSHolding(s) in Company
22nd Jun 20184:47 pmRNSHolding(s) in Company
20th Jun 20182:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.